Sharper definitions, blurred lines: The clinical aftermath of the revised antiphospholipid syndrome criteria

Read full text Summarise with VIRAT
Authors: Lauren E. Merz, Annemarie E. Fogerty
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The revised criteria for antiphospholipid antibody syndrome (APS) proposed in 2023 by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)1 have introduced a conundrum in the diagnosis and management of affected patients, particularly those with a history of obstetric APS. An increasingly common challenge is the management of patients who met the 2006 Sapporo criteria for obstetric APS and were managed accordingly with anticoagulation and aspirin in a prior pregnancy, but with the same laboratory and clinical history do not meet the 2023 criteria for a subsequent pregnancy. Whether to continue management based on the old criteria versus to inform the patients they no longer have the disease or indication for active management is an increasingly posed question without a definitive data-supported answer. APS is an autoimmune disorder characterized by persistent antiphospholipid antibodies—namely, lupus anticoagulant (LAC), anticardiolipin (aCL), or β2-glycoprotein-I (β2GPI) as well as specific vascular or thrombotic complications. The 2006 Sapporo criteria were intended to standardize APS cohorts in research settings but were soon widely adopted as clinical criteria for APS as well. These criteria are dichotomous and relatively simple: one clinical criterion and one laboratory criterion were required for a diagnosis. The 2023 ACR/EULAR criteria introduce a weighted system for both laboratory and clinical criteria and include additional clinical criteria such as thrombocytopenia and livedo reticularis.1 The 2006 Sapporo criteria and 2023 ACR/EULAR criteria are compared in Table 1. Given these changes, many patients who had previously been diagnosed with APS no longer meet the revised criteria. We illustrate a common case of reclassification with our expert approach and review of available data: A 28-year-old female has had three spontaneous abortions at 7, 9, and 8 weeks gestation. Fetal karyotype showed no abnormalities in the two losses that had genetic testing performed. She has no history of venous or arterial thrombosis, cardiac valve issues, thrombocytopenia, or microvascular disease. LAC and β2GPI were negative, but aCL IgG was high titer by ELISA twice, 12 weeks apart. The patient is now pregnant at 4 weeks gestation. She asks if she has obstetric APS and what the recommended management is to improve her chances of a live delivery. This patient meets the 2006 clinical and laboratory criteria for an obstetric APS diagnosis and continues to meet laboratory criteria by the 2023 definition, but has only 1 of 3 points required to satisfy the 2023 clinical criteria.1 Studies have shown that ~15% of patients previously classified as thrombotic APS do not meet the 2023 criteria due to lower antibody titers, IgM-only positivity, or the presence of exclusion diagnoses.2, 3 However, nearly a quarter of those reclassified had a thrombotic event during follow-up.2 Additionally, one study showed that only a quarter of patients who met the 2006 obstetric criteria also met the 2023 ACR/EULAR criteria.4 In fact, it is impossible to meet clinical criteria on 3+ early losses (

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Vasculitis and related conditions Reproductive System and Pregnancy

Publication details

Journal / source
HemaSphere
Volume
10
Issue
3
Pages
e70326–e70326
Publication date
1 March 2026
Language
EN